300966.Sz

The company's capital structure is characterized by a debt-to-equity ratio of 1.59, indicating a relatively high level of leverage. Liquidity is assessed as medium, with a current ratio of 0.94, suggesting the company may face challenges in meeting short-term obligations. Free cash flow is negative at -163,040,710 CNY, and capital expenditures are also negative at -166,326,360 CNY, indicating significant investment in long-term assets.

Profitability metrics show a return on equity of -8.88% and a return on assets of -2.57%, both below the industry median for pharmaceutical companies. The company reported a net loss of 73,359,120 CNY and an operating loss of 104,772,850 CNY, reflecting poor operational performance. Gross profit of 72,931,910 CNY is insufficient to cover operating expenses, contributing to the net loss.

The company's revenue is not segmented by product or geographic region in the available data, but the total revenue of 606,178,270 CNY is reported for the period. There is no indication of geographic diversification or segment-specific performance in the provided financials.

The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. Historical revenue data does not show a clear trend of growth or decline, and the company's operating cash flow of 41,036,390 CNY is insufficient to support significant expansion.

Risk factors include a high debt-to-equity ratio and negative free cash flow, which could limit the company's ability to invest in growth opportunities or withstand financial stress. Dilution is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. No recent events, such as filings or transcripts, are provided to indicate material changes in the company's risk profile.

No recent events, such as filings or transcripts, are provided in the available data to indicate material changes in the company's operations or financial position.